EMCUREPharmaceuticals
Emcure Pharmaceuticals Ltd — Balance Sheet
₹1595.50
+4.14%
Emcure Pharmaceuticals Ltd Balance Sheet (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Construction In Progress | 140.99 Cr | 146.40 Cr | 419.57 Cr | 340.76 Cr | — |
| Other Properties | 343.03 Cr | 321.57 Cr | 255.07 Cr | 222.02 Cr | — |
| Machinery Furniture Equipment | 2.43K Cr | 2.27K Cr | 1.83K Cr | 1.62K Cr | — |
| Buildings And Improvements | 907.60 Cr | 832.06 Cr | 680.77 Cr | 615.47 Cr | — |
| Land And Improvements | 151.58 Cr | 153.40 Cr | 150.46 Cr | 149.37 Cr | — |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Current Assets | 4.56K Cr | 4.26K Cr | 3.84K Cr | 3.42K Cr | — |
| Other Current Assets | 5.94 Cr | 4.22 Cr | 7.46 Cr | 5.36 Cr | — |
| Assets Held For Sale Current | 0.00 | 5.42 Cr | 0.00 | 0.00 | — |
| Restricted Cash | 33.71 Cr | 60.04 Cr | 185.98 Cr | 86.83 Cr | — |
| Prepaid Assets | 322.01 Cr | 265.36 Cr | 279.94 Cr | 294.23 Cr | — |
| Inventory | 1.93K Cr | 1.53K Cr | 1.38K Cr | 1.45K Cr | — |
| Finished Goods | 1.02K Cr | 769.32 Cr | 680.97 Cr | 744.12 Cr | — |
| Work In Process | 265.06 Cr | 253.44 Cr | 151.60 Cr | 155.14 Cr | — |
| Raw Materials | 645.52 Cr | 502.34 Cr | 550.46 Cr | 550.16 Cr | — |
| Ordinary Shares Number | 18.95 Cr | 18.91 Cr | 18.91 Cr | 18.91 Cr | — |
| Share Issued | 18.95 Cr | 18.91 Cr | 18.91 Cr | 18.91 Cr | — |
| Net Debt | 609.88 Cr | 1.98K Cr | 2.14K Cr | 2.01K Cr | — |
| Total Debt | 1.02K Cr | 2.33K Cr | 2.33K Cr | 2.22K Cr | — |
| Tangible Book Value | 3.50K Cr | 2.07K Cr | 2.16K Cr | 1.61K Cr | — |
| Invested Capital | 5.18K Cr | 5.04K Cr | 4.70K Cr | 4.07K Cr | — |
| Working Capital | 1.89K Cr | 1.05K Cr | 816.72 Cr | 459.27 Cr | — |
| Net Tangible Assets | 3.50K Cr | 2.07K Cr | 2.16K Cr | 1.61K Cr | — |
| Capital Lease Obligations | 291.05 Cr | 247.66 Cr | 139.37 Cr | 133.57 Cr | — |
| Common Stock Equity | 4.45K Cr | 2.95K Cr | 2.50K Cr | 1.99K Cr | — |
| Total Capitalization | 4.64K Cr | 3.72K Cr | 3.25K Cr | 2.70K Cr | — |
| Total Equity Gross Minority Interest | 4.64K Cr | 3.12K Cr | 2.65K Cr | 2.11K Cr | — |
| Minority Interest | 195.37 Cr | 169.48 Cr | 148.53 Cr | 126.59 Cr | — |
| Stockholders Equity | 4.45K Cr | 2.95K Cr | 2.50K Cr | 1.99K Cr | — |
| Other Equity Interest | 11.86 Cr | 14.50 Cr | 14.85 Cr | 15.92 Cr | — |
| Retained Earnings | 3.31K Cr | 2.63K Cr | 2.20K Cr | 1.70K Cr | — |
| Additional Paid In Capital | 785.25 Cr | 9.88 Cr | 0.00 | 0.00 | — |
| Capital Stock | 189.48 Cr | 181.15 Cr | 180.85 Cr | 180.85 Cr | — |
| Common Stock | 189.48 Cr | 181.15 Cr | 180.85 Cr | 180.85 Cr | — |
| Total Liabilities Net Minority Interest | 3.59K Cr | 4.68K Cr | 4.02K Cr | 3.95K Cr | — |
| Total Non Current Liabilities Net Minority Interest | 922.90 Cr | 1.47K Cr | 1.00K Cr | 984.50 Cr | — |
| Other Non Current Liabilities | 14.49 Cr | — | — | — | — |
| Non Current Pension And Other Postretirement Benefit Plans | 47.58 Cr | 43.32 Cr | 39.66 Cr | 42.10 Cr | — |
| Tradeand Other Payables Non Current | 243.08 Cr | 236.44 Cr | — | — | 58.48 Cr |
| Non Current Deferred Revenue | 14.49 Cr | 16.27 Cr | 16.29 Cr | 27.24 Cr | — |
| Non Current Deferred Taxes Liabilities | 120.03 Cr | 137.42 Cr | 38.90 Cr | 42.61 Cr | — |
| Long Term Debt And Capital Lease Obligation | 447.25 Cr | 982.34 Cr | 859.32 Cr | 828.56 Cr | — |
| Long Term Capital Lease Obligation | 257.32 Cr | 215.74 Cr | 115.18 Cr | 111.28 Cr | — |
| Long Term Debt | 189.94 Cr | 766.60 Cr | 744.13 Cr | 717.28 Cr | — |
| Long Term Provisions | 47.58 Cr | — | — | — | — |
| Current Liabilities | 2.67K Cr | 3.21K Cr | 3.02K Cr | 2.96K Cr | — |
| Other Current Liabilities | 15.81 Cr | 15.32 Cr | 8.41 Cr | 1.21 Cr | — |
| Current Debt And Capital Lease Obligation | 575.50 Cr | 1.35K Cr | 1.47K Cr | 1.39K Cr | — |
| Current Capital Lease Obligation | 33.73 Cr | 31.92 Cr | 24.19 Cr | 22.30 Cr | — |
| Current Debt | 541.77 Cr | 1.32K Cr | 1.45K Cr | 1.37K Cr | — |
| Current Provisions | 54.51 Cr | 45.73 Cr | 0.34 Cr | 0.24 Cr | — |
| Payables | 1.94K Cr | 1.69K Cr | 1.42K Cr | 1.44K Cr | — |
| Other Payable | 343.35 Cr | 328.70 Cr | 280.90 Cr | 254.85 Cr | — |
| Total Tax Payable | 112.30 Cr | 53.45 Cr | 48.77 Cr | 62.15 Cr | — |
| Accounts Payable | 1.48K Cr | 1.31K Cr | 1.09K Cr | 1.13K Cr | — |
| Total Assets | 8.23K Cr | 7.81K Cr | 6.67K Cr | 6.06K Cr | — |
| Total Non Current Assets | 3.68K Cr | 3.55K Cr | 2.84K Cr | 2.64K Cr | — |
| Other Non Current Assets | 38.89 Cr | — | 10000.00 | — | — |
| Non Current Prepaid Assets | 58.64 Cr | 44.39 Cr | 41.15 Cr | 30.76 Cr | — |
| Non Current Deferred Taxes Assets | 110.99 Cr | 96.80 Cr | 99.13 Cr | 116.08 Cr | — |
| Investmentin Financial Assets | 20.99 Cr | 18.69 Cr | 55.78 Cr | 44.04 Cr | — |
| Available For Sale Securities | 20.99 Cr | 18.69 Cr | 55.78 Cr | 44.04 Cr | — |
| Goodwill And Other Intangible Assets | 947.01 Cr | 886.45 Cr | 343.55 Cr | 378.75 Cr | — |
| Other Intangible Assets | 579.23 Cr | 507.77 Cr | 125.81 Cr | 161.36 Cr | — |
| Goodwill | 367.77 Cr | 378.69 Cr | 217.74 Cr | 217.40 Cr | — |
| Net PPE | 2.44K Cr | 2.41K Cr | 2.23K Cr | 2.02K Cr | — |
| Accumulated Depreciation | -1.53K Cr | -1.31K Cr | -1.10K Cr | -931.58 Cr | — |
| Gross PPE | 3.98K Cr | 3.72K Cr | 3.34K Cr | 2.95K Cr | — |
| Other Receivables | 53.20 Cr | 83.62 Cr | 70.36 Cr | 58.20 Cr | — |
| Accounts Receivable | 2.00K Cr | 1.86K Cr | 1.65K Cr | 1.31K Cr | — |
| Allowance For Doubtful Accounts Receivable | -95.50 Cr | -63.43 Cr | -49.60 Cr | -38.48 Cr | — |
| Gross Accounts Receivable | 2.10K Cr | 1.92K Cr | 1.70K Cr | 1.35K Cr | — |
| Cash Cash Equivalents And Short Term Investments | 206.95 Cr | 457.34 Cr | 260.85 Cr | 221.56 Cr | — |
| Other Short Term Investments | 85.13 Cr | 348.39 Cr | 204.48 Cr | 145.54 Cr | — |
| Cash And Cash Equivalents | 121.82 Cr | 108.96 Cr | 56.37 Cr | 76.02 Cr | — |
| Cash Financial | 121.82 Cr | 108.96 Cr | 56.37 Cr | 76.02 Cr | — |
| Pensionand Other Post Retirement Benefit Plans Current | — | 45.73 Cr | 39.75 Cr | 43.63 Cr | 41.42 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Emcure Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.